Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Incyte Corp. (INCY) shares rose 4.05% to $128.47 on Wednesday, outperforming the broader market but underperforming key competitors like Alnylam and Bio-Techne. The stock closed 3.11% below its 52-week high of $132.60. Trading volume was lower than the 50-day average, indicating mixed relative performance despite daily gains.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) advanced 4.05% to $128.47 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.21% to 7,707.98 and the Dow Jones Industrial Average rising 0.22% to 53,463.05.
Incyte Corp. closed 3.11% short of its 52-week high of $132.60, which the company reached on July 28th.
The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 6.12% to $242.61, Bio-Techne Corp. (TECH) rose 0.36% to $72.48, and BioMarin Pharmaceutical Inc. (BMRN) rose 3.49% to $69.33.
Trading volume (1.6 M) remained 347,803 below its 50-day average volume of 1.9 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 19, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-19-26 1702ET